Will the FDA give emergency use authorization or otherwise approve Molnupiravir before 2022?

This market will resolve to “Yes” if, by December 31, 2021, 11:59:59 PM ET, Molnupiravir (also known under MK-4482, EIDD-2801 or Lagervio), or any product containing it receives an Emergency Use Authorization (EUA) or full approval from the FDA for treating COVID-19. Otherwise, this market will resolve to “No.” If the resolution source isn’t updated by the resolution date, credible news reports may be used instead. ---------------------------- Molnupilavir, sold under the brand name Lagevrio among others, is an antiviral medication that inhibits the replication of certain RNA viruses, is used to treat COVID-19 in those infected by SARS-CoV-2 and is already approved by official health agencies in various countries (ie. UK, Bangladesh). Learn more about it: https://en.wikipedia.org/wiki/Molnupiravir https://www.ema.europa.eu/en/news/covid-19-ema-starts-rolling-review-molnupiravir https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra